Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 6/20 | 0.48 |
| ▸ | TMEM97 | Q5BJF2 | 6/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.48 |
| ▸ | DRD2 | P14416 | 3/20 | 0.43 |
| ▸ | DRD3 | P35462 | 3/20 | 0.43 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.41 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.40 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.40 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.40 |
| ▸ | CSF1R | P07333 | 1/20 | 0.40 |
| ▸ | CDK4 | P11802 | 1/20 | 0.40 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.40 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.40 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.37 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24316260 | 0.87 | KCNH2 (0.48) | KCNH2TMEM97SIGMAR1DRD2DRD3 | |
| SCHEMBL13243094 | 0.84 | KCNH2 (0.58) | KCNH2TMEM97SIGMAR1DRD2DRD3 | |
| SCHEMBL22436028 | 0.81 | NOTUM (0.38) | KCNH2DRD3CSF1RCDK4CDK6 | |
| SCHEMBL21361602 | 0.80 | ADRA2A (0.57) | KCNH2TMEM97SIGMAR1DRD2NOTUM | |
| SCHEMBL21216374 | 0.80 | BCL2L1 (0.46) | KCNH2DRD2DRD3P2RY1 | |
| SCHEMBL15845886 | 0.80 | CARM1 (0.49) | KCNH2DRD3CARM1 | |
| SCHEMBL19755625 | 0.80 | HRH3 (0.36) | KCNH2TMEM97SIGMAR1DRD3CSF1R | |
| SCHEMBL12878740 | 0.79 | ALDH1A1 (0.38) | KCNH2TMEM97SIGMAR1NOTUM | |
| SCHEMBL25465443 | 0.78 | ACACB (0.38) | KCNH2DRD3TRPV3CSF1RCDK4 | |
| SCHEMBL24317412 | 0.78 | KMT2A (0.37) | KCNH2TMEM97SIGMAR1DRD3CSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | C 4 Therapeutics, Inc. (US) | 2024-01-18 | — | — | US | disclosed |
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | C 4 Therapeutics, Inc. (US) | 2024-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | NFATC1, CTSS, MMP12 | KCNH2 4811/4885TMEM97 3680/4885SIGMAR1 3709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.